B-cell type acute leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png B-cell type acute leukaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy https://clinicaltrials.eu/trial/optimizing-fludarabine-phosphate-exposure-to-improve-event-free-survival-in-children-and-young-adults-with-b-cell-acute-lymphoblastic-leukemia-receiving-car-t-therapy/ Wed, 27 May 2026 04:05:22 +0000 https://clinicaltrials.eu/trial/optimizing-fludarabine-phosphate-exposure-to-improve-event-free-survival-in-children-and-young-adults-with-b-cell-acute-lymphoblastic-leukemia-receiving-car-t-therapy/ The study focuses on children and young adults who have B-cell Acute Lymphoblastic Leukemia that has returned after previous treatment or did not respond to it. Participants receive a medication called fludarabine before being given CAR T cell therapy, a treatment where a patient’s own immune cells are engineered to attack the cancer. The main aim of the trial is to compare the EFS between patients who receive the usual dose of fludarabine and those whose dose is adjusted to reach a specific drug level.

After giving consent, participants are randomly assigned to either the standard fludarabine dosing group or the target‑level dosing group. All patients then undergo the CAR T cell infusion and are followed for several months to monitor how long they remain free of disease progression, need for new leukemia treatment, or other serious complications. Visits include routine check‑ups, blood tests, and simple questionnaires about how they feel, allowing researchers to see whether the adjusted dosing improves outcomes and safety.

]]> A Study to Test the Safety and How AZD4512 Works in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/a-study-to-test-the-safety-and-how-azd4512-works-in-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ Thu, 30 Apr 2026 13:08:30 +0000 https://clinicaltrials.eu/trial/a-study-to-test-the-safety-and-how-azd4512-works-in-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ This study involves people with B-cell acute lymphoblastic leukemia, which is a type of blood cancer where the bone marrow makes too many immature white blood cells called lymphoblasts. The study focuses on cases where the disease has either come back after treatment or has not responded to previous treatments. The treatment being tested is AZD4512, which is an experimental medicine given through a vein as an infusion. The medicine is being tested both in people whose disease has a certain genetic marker called Philadelphia chromosome positive and in those without this marker, although later parts of the study will focus only on those without the marker.

The purpose of the study is to find out how safe AZD4512 is, what dose works best, and whether it can help control the leukemia. The study will also look at how the medicine moves through the body, whether the body develops an immune response to it, and how well it works against the cancer. The study is divided into different modules, with the first module testing different doses to find the safest and most effective amount, and the second module testing the chosen dose in more people to better understand how well it works.

During the study, participants will receive AZD4512 through an intravenous infusion, and doctors will closely monitor them for any side effects or changes in their condition. The study will measure whether the cancer responds to treatment by checking if cancer cells in the bone marrow decrease or disappear, and whether any remaining cancer cells can be detected using sensitive testing methods. Participants will have regular check-ups, blood tests, and bone marrow tests to see how the treatment is working and to monitor their overall health throughout the study.

]]> Comparing human normal immunoglobulin (iv) and a drug combination to prevent infections in adults with B-cell acute lymphoblastic leukemia or B-cell lymphoma treated with CAR-T cells https://clinicaltrials.eu/trial/comparing-human-normal-immunoglobulin-iv-and-a-drug-combination-to-prevent-infections-in-adults-with-b-cell-acute-lymphoblastic-leukemia-or-b-cell-lymphoma-treated-with-car-t-cells/ Wed, 29 Apr 2026 15:09:55 +0000 https://clinicaltrials.eu/trial/comparing-human-normal-immunoglobulin-iv-and-a-drug-combination-to-prevent-infections-in-adults-with-b-cell-acute-lymphoblastic-leukemia-or-b-cell-lymphoma-treated-with-car-t-cells/ This study focuses on individuals treated with CAR-T cells, a type of immunotherapy used to fight certain cancers. Specifically, the research involves patients with B-cell acute lymphoblastic leukemia, a type of blood cancer, or B-cell lymphoma, a cancer of the immune system. Following this treatment, patients may be at a higher risk for infections. The purpose of the study is to compare two different ways to prevent these infections.

One method being studied is immunoglobulin replacement therapy, which involves the administration of human normal immunoglobulin through an intravenous line, meaning it is delivered directly into a vein. The other method is antibiotic prophylaxis, which is the use of medications to prevent infections before they occur. The medications used for comparison in this study include amoxicillin trihydrate, sulfamethoxazole, trimethoprim, bromhexine hydrochloride, levofloxacin, amoxicillin sodium, and azithromycin.

Participants in the study will be assigned to one of the two prevention methods. During the follow-up period, which lasts for 12 months, the occurrence of infections will be monitored. This includes looking for recurrent infections that require treatment or severe infections that lead to a hospital stay.

]]> A Study Testing the Safety of CD19-Targeted CAR T-Cell Therapy in Children and Young Adults with Relapsed or Refractory B-Cell Cancers https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ Wed, 29 Apr 2026 15:08:31 +0000 https://clinicaltrials.eu/trial/a-study-testing-the-safety-of-cd19-targeted-car-t-cell-therapy-in-children-and-young-adults-with-relapsed-or-refractory-b-cell-cancers/ This study is looking at two types of cancer that affect certain white blood cells. The first is B-cell precursor ALL, which is a cancer where the bone marrow makes too many immature white blood cells. The second is B-cell Non Hodgkin Lymphoma, which is a cancer that starts in white blood cells called lymphocytes and can affect lymph nodes and other parts of the body. Both of these cancers have either come back after previous treatment or have not responded to treatment. The study will use a treatment called MB-huCART19.1, which is a type of therapy where a patient’s own immune cells are collected and modified in a laboratory to better recognize and attack cancer cells that have a specific marker called CD19 on their surface. These modified cells, known as CAR T-cells, are then given back to the patient through intravenous infusion, which means the cells are delivered directly into a vein.

The purpose of this study is to find out the safest dose of these modified cells that can be given to patients and to see how well the treatment works. The study will look at how many patients experience serious side effects within 28 days after receiving the treatment, which will help determine the best dose to use in the next part of the study. The study will also measure how well the treatment works by checking if the cancer responds to the treatment and how long patients remain free from disease.

During the study, patients will first have their own immune cells collected. These cells will then be modified in a laboratory to target the cancer cells. Before receiving the modified cells back, patients may receive chemotherapy to prepare their body for the treatment. After the modified cells are given through an infusion into a vein, patients will be monitored closely for side effects and to see how well the treatment is working. The study will follow patients for up to 12 months to track their progress and see if the cancer comes back. This study is for children and young adults between 1 and 45 years of age who have tried other treatments that did not work or who cannot receive other standard treatments.

]]> Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia https://clinicaltrials.eu/trial/study-of-chemotherapy-with-blinatumomab-and-tyrosine-kinase-inhibitors-in-newly-diagnosed-children-and-young-adults-with-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:08:19 +0000 https://clinicaltrials.eu/trial/study-of-chemotherapy-with-blinatumomab-and-tyrosine-kinase-inhibitors-in-newly-diagnosed-children-and-young-adults-with-philadelphia-chromosome-positive-b-cell-acute-lymphoblastic-leukemia/ This study involves patients with two types of B-cell Acute Lymphoblastic Leukemia, which is a cancer of the blood and bone marrow where the body makes too many immature white blood cells. The first type is called Philadelphia Chromosome Positive leukemia, which has a specific genetic change involving a chromosome abnormality called BCR::ABL1. The second type is called ABL-class Philadelphia Chromosome-Like leukemia, which behaves similarly to the first type and has genetic changes involving certain genes that include ABL1, ABL2, CSF1R, and PDGFRB. The treatment being tested combines chemotherapy with a medication called blinatumomab, which is given through a vein, along with targeted drugs called tyrosine kinase inhibitors. Patients with Philadelphia Chromosome Positive leukemia will receive dasatinib, while those with ABL-class leukemia will receive either imatinib if they have PDGFRB gene changes or dasatinib if they do not.

The purpose of this study is to measure how well this treatment combination works over a three-year period and to examine its safety in children, adolescents, and young adults with these types of leukemia. The treatment approach uses a modified chemotherapy plan that includes three cycles of blinatumomab without traditional consolidation chemotherapy, combined with continuous use of the targeted drugs. The study will track various side effects including infections, mouth sores, nerve problems, cytokine release syndrome which is a reaction from the immune system, low levels of protective antibodies in the blood, treatment delays, and deaths related to treatment.

During the study, patients will receive a combination of standard chemotherapy drugs including vincristine, steroids, and pegaspargase or calaspargase pegol, with or without an anthracycline drug. The treatment plan is designed to work differently for the two types of leukemia, with patients having already started some initial therapy before joining the study. The study will follow patients to see how many remain free from disease events over three years and will also track overall survival rates and how the treatment works based on the specific genetic changes present in each patient’s leukemia.

]]> Study of LUMC-BOB1-B7-TCR. https://clinicaltrials.eu/trial/study-of-lumc-bob1-b7-tcr/ Wed, 29 Apr 2026 15:07:28 +0000 https://clinicaltrials.eu/trial/study-of-lumc-bob1-b7-tcr/ This clinical trial studies the treatment of blood cancers including Multiple Myeloma, Non-Hodgkin B-cell lymphoma, and B-cell Acute Lymphoblastic Leukemia that have either returned after previous treatment or did not respond to standard treatments. The study uses a new treatment called LUMC-BOB1-B7-TCR.1, which is made from the patient’s own immune cells (specifically T cells) that have been modified in a laboratory to better fight cancer cells.

The purpose of this study is to determine if this new cell therapy treatment is safe to use and if it works effectively against these blood cancers. The treatment is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. This is a combined Phase 1 and Phase 2 study, where Phase 1 focuses on finding the right dose of the treatment, and Phase 2 examines how well the treatment works.

The treatment involves taking some of the patient’s own immune cells, modifying them in a laboratory to recognize and attack cancer cells, and then returning them to the patient through an infusion. After receiving the treatment, patients will be monitored for side effects and to see how their cancer responds to the therapy. The study specifically looks at patients whose cancer cells have a particular genetic marker called HLA-B*07:02.

]]> Study on Pegaspargase and Rituximab for Treating Children with Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-pegaspargase-and-rituximab-for-treating-children-with-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 15:02:11 +0000 https://clinicaltrials.eu/trial/study-on-pegaspargase-and-rituximab-for-treating-children-with-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of cancer called Childhood Acute Lymphoblastic Leukemia (ALL), which affects the blood and bone marrow. The study will explore the effectiveness of two treatments: Oncaspar, which contains the active substance pegaspargase, and Riximyo, which contains rituximab. These medications are given through an infusion, which means they are delivered directly into the bloodstream.

The purpose of the study is to find new strategies to improve treatment for children with ALL. The study will look at how well these treatments work in improving survival rates and reducing complications. It will also explore the role of intensified treatment with pegaspargase and the impact of immunotherapy, which is a type of treatment that uses the body’s immune system to fight cancer, specifically using rituximab for patients with a subtype of ALL known as B-cell precursor ALL.

Participants in the study will receive either the study medication or a placebo. The study will monitor the participants over a period of time to assess the effectiveness and safety of the treatments. This includes checking for any side effects and measuring how the cancer responds to the treatment. The study aims to provide valuable information that could lead to better treatment options for children with ALL in the future.

]]> Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-brexucabtagene-autoleucel-for-children-and-teens-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-non-hodgkin-lymphoma/ Wed, 29 Apr 2026 14:59:11 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-brexucabtagene-autoleucel-for-children-and-teens-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-or-non-hodgkin-lymphoma/ This clinical trial is focused on studying two types of blood cancers: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia and Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. These are conditions where the cancer has returned or has not responded to previous treatments. The treatment being tested in this study is called KTE-X19, which is a type of cell therapy. This therapy involves using a patient’s own immune cells, which are modified in a laboratory to better recognize and attack cancer cells. The modified cells are then infused back into the patient to help fight the cancer.

The purpose of the study is to evaluate the safety and effectiveness of KTE-X19 in children and adolescents with these types of blood cancers. The study is divided into two phases. In the first phase, the focus is on assessing the safety of the treatment. In the second phase, the study aims to determine how well the treatment works in achieving remission, which means the cancer is no longer detectable. Participants will receive the treatment through an intravenous infusion, which is a method of delivering medication directly into the bloodstream.

Throughout the study, participants will be closely monitored for any side effects and to see how their cancer responds to the treatment. The study will also look at how long any remission lasts and overall survival rates. This research is important for understanding how effective KTE-X19 is in treating these challenging forms of cancer in young patients.

]]> Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel https://clinicaltrials.eu/trial/long-term-follow-up-study-for-patients-treated-with-car-t-cell-therapy-using-phe885-ytb323-and-tisagenlecleucel/ Wed, 29 Apr 2026 14:57:09 +0000 https://clinicaltrials.eu/trial/long-term-follow-up-study-for-patients-treated-with-car-t-cell-therapy-using-phe885-ytb323-and-tisagenlecleucel/ This clinical trial is focused on the long-term follow-up of patients who have been treated with a type of therapy known as CAR T-cell therapy. This therapy involves using a patient’s own immune cells, called T-cells, which are modified to better recognize and attack cancer cells. The study includes patients who have received this treatment for various conditions, using products developed by Novartis or Penn. The main purpose of the study is to observe and describe any delayed side effects that might be related to the previous CAR T-cell therapy.

The study involves several treatments, including PHE885, YTB323, and Tisagenlecleucel. These treatments are given as a dispersion for infusion, which means they are administered directly into the bloodstream through an intravenous infusion. PHE885 uses a patient’s own T-cells that are engineered to target a specific protein on cancer cells called the B cell maturation antigen. YTB323 involves T-cells that are modified to target another protein known as CD19. Tisagenlecleucel is also a type of CAR T-cell therapy that targets cancer cells using a similar approach.

Throughout the study, researchers will monitor patients for any new health issues that may arise after receiving CAR T-cell therapy. This includes checking for new cancers, serious infections, neurological disorders, autoimmune conditions, and blood disorders. The study will also track the presence of the modified T-cells in the blood over time and observe any changes in the patient’s health status, such as relapse or progression of their condition. The study aims to provide valuable information on the long-term safety and effects of CAR T-cell therapy.

]]> Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN https://clinicaltrials.eu/trial/study-of-sar443579-infusion-for-adults-and-children-with-relapsed-or-refractory-acute-myeloid-leukemia-b-cell-acute-lymphoblastic-leukemia-hr-mds-or-bpdcn/ Wed, 29 Apr 2026 14:47:53 +0000 https://clinicaltrials.eu/trial/study-of-sar443579-infusion-for-adults-and-children-with-relapsed-or-refractory-acute-myeloid-leukemia-b-cell-acute-lymphoblastic-leukemia-hr-mds-or-bpdcn/ This clinical trial is focused on studying the effects of a new treatment called in individuals with certain types of blood cancers. These include , , , and . The treatment, , is administered through an intravenous infusion, which means it is given directly into the bloodstream through a vein.

The purpose of the study is to find the most suitable dose of that can be safely given to patients and to evaluate its effectiveness in treating these blood cancers. The study is divided into two parts. In the first part, the focus is on determining the best dose for both adults and children. In the second part, the study aims to assess how well the treatment works at the recommended dose. Participants will receive the treatment and be monitored for any side effects and improvements in their condition.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their cancer. The study will help researchers understand more about the potential benefits and risks of for treating these serious conditions. The information gathered from this trial could contribute to developing new treatment options for patients with these types of blood cancers.

]]> Study on CD19-CAR T Cells, Fludarabine, and Cyclophosphamide for Children and Young Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-cd19-car-t-cells-fludarabine-and-cyclophosphamide-for-children-and-young-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:30:08 +0000 https://clinicaltrials.eu/trial/study-on-cd19-car-t-cells-fludarabine-and-cyclophosphamide-for-children-and-young-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), which can be challenging to treat. The study is testing a new treatment involving special cells known as CD19-CAR T cells. These are a type of cell therapy where T cells, a part of the immune system, are modified to better recognize and attack cancer cells. The specific treatment being tested is called CD19-CAR_Lenti_ALLO, which is a second-generation version of these cells. The trial aims to find out how safe this treatment is and to determine the best dose for children and young adults who have this type of leukemia.

Participants in the study will receive the CD19-CAR_Lenti_ALLO treatment through an injection. Before receiving this treatment, they may also be given other medications, such as Fludara (fludarabine phosphate) and Cyclophosphamide, which are used to prepare the body for the new cells. These medications help to create a suitable environment for the CD19-CAR T cells to work effectively. The study will monitor the participants closely to see how they respond to the treatment and to check for any side effects.

The purpose of this study is to evaluate the safety of the CD19-CAR_Lenti_ALLO treatment and to establish the recommended dose for patients. The trial will also look at how well the treatment works in reducing the cancer cells in the body. Participants will be observed over a period of time to assess the treatment’s impact on their health and to gather information that could help improve future treatments for B-ALL. The study is expected to continue until 2027, with recruitment starting in 2024.

]]> Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-azd0486-and-tocilizumab-for-adolescents-and-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:29:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-azd0486-and-tocilizumab-for-adolescents-and-adults-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The trial is investigating a new treatment called AZD0486, which is a special kind of medicine known as a human IgG4 kappa monoclonal antibody. This medicine is designed to target specific proteins on cancer cells, known as CD3 and CD19. The study will also involve another medication called tocilizumab, which is already used in other treatments.

The purpose of the study is to determine if AZD0486 is safe and effective for people with B-ALL that has either returned after treatment or has not responded to previous treatments. Participants in the study will receive AZD0486 through an infusion, which means the medicine will be given directly into a vein. The study will be conducted in different parts, with each part focusing on different age groups and specific characteristics of the disease. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of AZD0486.

Throughout the study, participants will be closely monitored to assess how well they tolerate the treatment and to observe any changes in their condition. The study aims to gather information on the safety of AZD0486 and its ability to help control the disease. The trial is expected to continue until the end of 2025, with recruitment starting in 2024. Participants will be involved in regular check-ups and assessments to track their progress and any side effects they may experience.

]]> Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas https://clinicaltrials.eu/trial/study-on-the-safety-of-epcoritamab-for-children-and-young-adults-with-relapsed-or-refractory-aggressive-b-cell-lymphomas/ Wed, 29 Apr 2026 14:26:10 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-epcoritamab-for-children-and-young-adults-with-relapsed-or-refractory-aggressive-b-cell-lymphomas/ This clinical trial is focused on studying a type of cancer known as Relapsed/Refractory Aggressive Mature B-cell Neoplasms, which includes specific subtypes like Burkitt’s lymphoma, Burkitt-like lymphoma, and Diffuse Large B-cell Lymphoma (DLBCL). These are aggressive forms of cancer that affect a type of white blood cell called B-cells. The study is testing a new treatment called Epcoritamab (GEN3013), which is a type of medicine known as a bispecific antibody. This medicine is given as a solution for injection under the skin.

The purpose of the study is to evaluate the safety and how the body processes Epcoritamab in children and young adults who have these types of B-cell cancers and have not responded to previous treatments. Participants in the study will receive the medication and be monitored for any side effects and how well the treatment is tolerated. The study will also look at how the medicine moves through and affects the body.

Throughout the study, researchers will observe participants for any serious side effects, such as Cytokine Release Syndrome (CRS), which is a reaction that can occur when the immune system is activated, and Immune Cell-Associated Neurotoxicity Syndrome (ICANS), which affects the nervous system. The study will also track how long participants live without the cancer getting worse, their overall survival, and the possibility of needing further treatments like stem cell transplants or CAR-T cell therapy. The study aims to provide valuable information about the potential benefits and risks of using Epcoritamab for treating these aggressive cancers in young patients.

]]> Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia https://clinicaltrials.eu/trial/study-of-ucart22-for-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ Wed, 29 Apr 2026 14:23:47 +0000 https://clinicaltrials.eu/trial/study-of-ucart22-for-patients-with-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ This clinical trial is focused on studying a type of blood cancer called B-cell Acute Lymphoblastic Leukemia (B-ALL), specifically in patients whose disease has returned or has not responded to previous treatments. The study is testing a new treatment called UCART22, which involves using specially engineered immune cells known as T-cells. These T-cells are designed to target and attack cancer cells that have a specific marker called CD22 on their surface. The purpose of the study is to evaluate the safety and effectiveness of UCART22 in treating this type of leukemia.

Participants in the study will receive UCART22 through an intravenous infusion, which means the treatment is delivered directly into the bloodstream. The study is divided into two parts: dose-escalation and dose-expansion. In the dose-escalation phase, different doses of UCART22 will be tested to find the safest and most effective dose. In the dose-expansion phase, the selected dose will be given to more patients to confirm its safety and effectiveness. Throughout the study, participants will be closely monitored for any side effects and to see how well the treatment works against the leukemia.

In addition to UCART22, some patients may receive other medications as part of their treatment plan. These include Alemtuzumab (also known as LEMTRADA or CLLS52), Rituximab (known as MabThera), Cyclophosphamide (known as ENDOXAN), and Fludarabine Phosphate (known as Fludara). These medications are used to help prepare the body for the UCART22 treatment and to support the overall treatment process. The study aims to provide valuable information on how UCART22 can be used to treat B-ALL and improve outcomes for patients with this challenging condition.

]]>